Hims & Hers Health is trading at €26.08, up 5.59%, with no company-specific catalyst reported. - On October 9, shares rose after a nearly 5% decline; volume was about 1.3 times the three-month average. - An October 9 broad-market rebound may have contributed, but does not establish a specific cause. - The FTC lawsuit and related securities litigation remain ongoing background, not a newly reported October 12 trigger.